| Date Filed | Type | Description |
| 09/19/2019 |
RW
| Form RW - Registration Withdrawal Request: |
| 05/09/2019 |
SC 13G/A
| Opko Health, Inc. reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC. |
| 04/24/2019 |
10-Q/A
| Quarterly Report for the period ended September 30, 2018 [amend] |
| 03/29/2019 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/29/2019 |
10-Q/A
| Quarterly Report for the period ended September 30, 2018 [amend] |
| 03/25/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 01/04/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/20/2018 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/20/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 11/13/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 10/22/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 10/16/2018 |
8-K
| Quarterly results |
| 10/15/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 10/15/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 10/15/2018 |
10-K/A
| Annual Report for the period ended December 31, 2017 [amend] |
| 09/27/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/06/2018 |
SC 13G
| Honig Barry C reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC. |
| 07/25/2018 |
SC 13D/A
| Stetson John reports a 5% stake in MABVAX THERAPEUTICS HOLDINGS, INC. |
| 07/09/2018 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/05/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...|
Docs:
|
"MabVax Therapeutics Receives Nasdaq Delist Determination San Diego, CA, July 5, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that as a result of the Company’s decision not to submit a plan to regain compliance with Nasdaq’s filing requirement, which decision was announced by the Company in a press release on July 2, 2018, on that same date, the Listing Qualifications Staff of The Nasdaq Stock Market LLC notified the Company of its determination to delist the Company’s securities from Nasdaq. The Staff indicated that the determination was based upon the Company’s non-compliance wi..." |
|
| 07/03/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 07/02/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 05/24/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 05/22/2018 |
8-K/A
| Financial Statements and Exhibits |
| 05/21/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previous... |
| 05/14/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/03/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"Certificate of Designations, Preferences and Rights of the 0% Series N Convertible Preferred Stock",
"Certificate of Correction to Certificate of Designations, Preferences and Rights of the 0% Series N Convertible Preferred Stock",
"Certificate of Designations, Preferences and Rights of the 0% Series O Convertible Preferred Stock",
"Form of Purchase Agreement",
"Form of Registration Rights Agreement",
"Form of May 2018 Letter Agreement",
"MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering SAN DIEGO, May 3, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced it has entered into securities purchase agreements with accredited investors pursuant to which the Company has agreed to sell $860,000 worth of shares of the Company’s newly designated 0% Series N Convertible Preferred Stock . Transaction costs are estimated to be $10,000. The initial conversion price for the Series N Preferred Stock is $1.10 per share of common stock. The offering is expected to close on or before May 7, 2018. In connection with this offering, the Company offered incentive sh..." |
|
| 05/03/2018 |
8-K
| Investor presentation |
| 04/18/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/13/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 04/04/2018 |
4/A
| Cohen Kenneth M (Director) has filed a Form 4 on MABVAX THERAPEUTICS HOLDINGS, INC.|
Txns:
| Exercised 513 restricted stock units
@ $0 |
|
| 04/04/2018 |
4/A
| MAIER PAUL V (Director) has filed a Form 4 on MABVAX THERAPEUTICS HOLDINGS, INC.|
Txns:
| Exercised 513 restricted stock units
@ $0 |
|
| 04/03/2018 |
4
| Varvaro Thomas C (Director) has filed a Form 4 on MABVAX THERAPEUTICS HOLDINGS, INC.|
Txns:
| Exercised 513 restricted stock units
@ $0 |
|
| 04/03/2018 |
4
| MAIER PAUL V (Director) has filed a Form 4 on MABVAX THERAPEUTICS HOLDINGS, INC.|
Txns:
| Exercised 513 restricted stock units
@ $0 |
|
|